Posted by Michael Wonder on 24 Jul 2018
Prescribing biosimilars
24 July 2018 - Slow adoption is costly.
Generic formulations of small molecules are usually as effective as originators, have similar harms, and are cheaper to prescribe. The same should be true of biosimilars, which are generic equivalents of originator biological medicines (biologics).
Two years ago we cited an article in the Financial Times, the author of which claimed that the UK had been slow to adopt biosimilars. Here we provide evidence that that is so, based on the limited publicly available information on NHS prescribing of biosimilars.
